A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear. METHODS: In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo. The trial had two phases: a 24-week rapid-dose-escalation phase, followed by a 24-week maintenance phase. The primary end point was histologic improvement (reduction) in MASH with no worsening of fibrosis. Secondary end points included a decrease in liver fat content by at least 30% and biopsy-assessed improvement (reduction) in fibrosis by at least one stage. RESULTS: A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model). A decrease in liver fat content by at least 30% occurred in 63% of the participants in the survodutide 2.4-mg group, 67% of those in the 4.8-mg group, 57% of those in the 6.0-mg group, and 14% of those in the placebo group; improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively. Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%); serious adverse events occurred in 8% with survodutide and 7% with placebo. CONCLUSIONS: Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304286 · Cited by 522
Self-citationGlucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Cited by
Items 301–400 of 537
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Winther‐Sørensen, M., Rasmussen, C. B., Trammell, S. A. J., Hansen, C., Vyberg, M., Serizawa, R., Richter, E. A., Grevengoed, T. J., Gluud, L. L., Kuhre, R. E., et al. (2025) · Peptides · doi:10.1016/j.peptides.2025.171462 · Cited by 2
Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects
Piazzolla, V., Napolitano, A., & Mangia, A. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.152 · Cited by 2
Andonie, C. R., Abusalameh, A., Ismail, I., Hodrob, T., Ladadweh, M., & Ayesh, H. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70157 · Cited by 2
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
“Importantly, next-generation AOMs, such as dual GLP-1/ glucagon agonists (survodutide) and triple GIP/GLP-1/ glucagon agonists (retatrutide) have shown promising results in both obesity management 113,114 and in MASLD/ MASH 115,116 in phase II RCTs.”
Zimmermann, T., Bleymehl, K., Haebel, P., Perens, J., Roostalu, U., Hecksher‐Sørensen, J., Doerr, J., Jarosch, S., Lam, D. D., Klein, H., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102326 · Cited by 5
“In Phase 2 studies survodutide demonstrated clinically relevant body weight lowering of up to 19% [1] and showed significant improvements in MASH resolution and fibrosis in people with MASH [2].”
Bartholdy, A., Moseholm, K. F., Nielsen, P. Y., Albrechtsen, N. J. W., Gluud, L. L., & Jensen, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01796-x · Cited by 3
“While previously only treatable through lifestyle interventions, several pharmacological treatments have recently shown promise in clinical trials (Sanyal et al. 2024; Harrison et al. 2025, 2024).”
Zheng, N., 涂龙芳, Xu, P., Chen, R., Lu, J., Dai, W., Lin, Y., Ouyang, J., Qiu, J., Wang, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03845 · Cited by 2
Wang, M., Jiang, Y.-N., Li, P.-P., & Wu, Y.-J. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s565093 · Cited by 2
“14,33,34,36,41 Pooled data indicated that there was no statistical significance in improvement in fibrosis without worsening of steatohepatitis between two groups (OR=1.54; 95% CI, [0.95, 2.48]; P=0.08; I 2 =58%).”
InfluentialSlaton, R. M., Iranikhah, M. G., & White, C. W. (2026) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2026.100032 · Cited by 4
Advances in the Pharmacologic Management of MASLD
Madhankumar, S., & Asma, A. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17010017 · Cited by 2
“…Phase 2b trial published in The New England Journal of Medicine , adults with biopsy-confirmed MASH (F1–F3) receiving survodutide achieved higher rates of MASH resolution without fibrosis worsening, substantial reductions in liver fat, and ≥ 1-stage fibrosis improvement compared with placebo [44].”
Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis
Lin, J., Huang, Y., Xu, B., Huang, C., Teng, F., Yuan, Y., Zhang, J., & Zhang, H. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70206 · Cited by 2
“In recent years, the therapeutic landscape for MASH has expanded rapidly, encompassing THR-β agonists [4], incretin-based agents (GLP-1 receptor agonists [5], dual/triple agonists [15, 16]), SGLT2 inhibitors [9], and emerging compounds such as pan-PPAR agonists [17] and FGF21 analogs [18, 19].”
Patil, R., Dunn, W., Noureddin, M., & Alkhouri, N. (2026) · Drugs · doi:10.1007/s40265-026-02301-5 · Cited by 2
Self-citationA review of survodutide: a new dual acting agonist
Yathindra, M. R., BHATTACHARJEE, A., PUNDIR, N., PATEL, P., Jacob, N. E., Jossy, P. E., & Seetharaman, R. (2026) · Minerva Endocrinology · doi:10.23736/s2724-6507.26.04406-4 · Cited by 2
Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams
Alexopoulos, A., & Cusi, K. J. (2026) · Diabetes Care · doi:10.2337/dci26-0019 · Cited by 3
Qiu, H., Tan, X., Sheng, Q., Yang, N., Jiang, C. M., & Wang, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118096 · Cited by 4
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
“…in histology-based disease improvement (e.g., a peak response reported at 4.8 mg versus placebo) alongside substantial reductions in liver fat assessed by noninvasive imaging; however, con - firmation of durability and fibrosis benefit requires larger, longer, late-stage trials [160 ].”
InfluentialAdvanced Peptide Modifications for Superior Therapeutics
Bhadra, J., De, N., Momin, M. S. A., Sannigrahi, A., & Bhunia, D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00826 · Cited by 2
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Noureddin, M., Dunn, W., Patil, R., Desai, D., Puskoor, R., Shin, J., To, D., BELL, A. C., Lee, D. R., Lin, Y.-H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00130-5 · Cited by 2
Self-citationMAFLD/MASLD: Past, Present, and Future
Wong, V. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70619 · Cited by 2
“New incretin therapies with dual or triple agonism targeting GLP-1, glucagon, and glucose-dependent insulinotropic polypeptide receptors promise to achieve even greater weight reduction and potentially more profound effects on MASH [67, 68].”
Current therapeutic landscape and future treatment perspectives of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10672-8 · Cited by 7
“Of note, a sub-analysis of the prospective SELECT study has found that 2.4 mg semaglutide significantly reduced major adverse cardiovascular events by 21–34% in patients with suspected MASLD across all FIB4 risk groups 127 , indicating a cardiovascular risk reduction in this population.”
InfluentialSelf-citationParadigm shift in steatotic liver disease (SLD): from NAFLD to MASLD
Yoneda, M., Kobayashi, T., Iwaki, M., Wada, N., Nogami, A., Takahashi, H., & Nakajima, A. (2024) · Kanzo · doi:10.2957/kanzo.65.420 · Cited by 2
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Stefan, N., & Roden, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2312-0452 · Cited by 2
“Stützende Quellenangabe: [24, 27] Vorbemerkung Die metabolische Dysfunktion-assoziierte steatotische Leberer-krankung (Metabolic Dysfunction-Associated Steatotic Liver Disease [MASLD]) betrifft weltweit 38% der erwachsenen Bevöl-kerung [1].”
Lemasters, J. J., & Zhong, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15260-3.00026-0 · Cited by 3
Wong, Y. J., & Goh, G. B. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-051 · Cited by 2
Zhou, Y., Wang, B., Wu, M., Hong, H., Li, G., & Xu, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-04502-6 · Cited by 2
Park, J., Kim, J. W., & Lim, S. (2025) · Annals of Nutrition and Metabolism · doi:10.1159/000547347 · Cited by 4
“A phase II trial showed that survodutide, a dual agonist of glucagon and GLP-1 receptors, improves metabolic associated steatohepatitis without worsening fibrosis [39].”
Dual Agonists for Management of Metabolic Dysfunction–Associated Steatohepatitis
Kanwal, F. (2024) · New England Journal of Medicine · doi:10.1056/nejme2406487 · Cited by 2
GLP-1 receptor agonists and MASLD in diabetes: A promising path?
Pennisi, G., Petta, S., Maggio, V., & Rizzo, M. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109041 · Cited by 3
A New Role for Glucagon: From Secondary Hormone to Key Player
De Fano, M., Malara, M., Rucco, S., Manco, M., Fanelli, C. G., Bolli, G. B., & Porcellati, F. (2025) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104233 · Cited by 1
Lee, J., & Shin, M. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e2 · Cited by 2
Burden of Obesity in Adults at a Tertiary Care Hospital
Bukasa-Kakamba, J., Wadhwani, S., Malu, E. N., Wadhwani, N., Latil-Plat, F., Poka, N., Kalambayi, I. K., Mutombo, M. B., Mohamed, A., Bangolo, A., et al. (2025) · Cureus · doi:10.7759/cureus.84776 · Cited by 2
Diagnose und Therapie der MASLD
Horn, P., & Tacke, F. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01896-3 · Cited by 1
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 6
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 2
“In a 48 week phase II trial on 293 participants with biopsy-confirmed MASH stage F1–F3, once weekly subcutaneous survodutide was administered at doses of 2.4, 4.8 or 6 mg along with a placebo arm [36].”
InfluentialЛазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024
Camilleri, M., & Dellon, E. S. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.06.001 · Cited by 1
Screening for MASLD in patients with type 2 diabetes: is an early diagnosis a good diagnosis?
Nwoguh, C. A., Byrne, C. D., Reinson, T., & Buchanan, R. M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2546597 · Cited by 2
“…[40], a glucagon-like peptide-1 (GLP-1) receptor agonist; tirzepatide [41], a dual glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide) plus GLP-1 receptor agonist, and pemvidutide and survodutide, GLP-1/glucagon dual receptor agonists [42,43].”
Lee, S. H., Kim, J. H., Lee, S. R., Lee, B. S., Kim, K. H., Jun, D. W., Kim, C. S., & Kang, K. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1707492 · Cited by 1
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?
Brennan, D. J., & Lynch, L. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0991 · Cited by 1
GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107184 · Cited by 1
Kim, T., Pearson, M. J., Hong, H., Nason, S. R., Seck, K., ANTIPENKO, J. P., Presedo, N., DiMarchi, R. D., Roell, W. C., & Habegger, K. M. (2025) · Obesity · doi:10.1002/oby.70087 · Cited by 2
Acuña, P., ALBHAISI, O. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Díaz, L. A., & Arab, J. P. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.61 · Cited by 2
Self-citationWang, Y., WANG, Z., Yan, G., Peng, C., Chen, L., Yan, R., & WANG, Q. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70495 · Cited by 1
“8,10,23,24,30 This study introduced SHG/TPEF imaging combined with AI-driven analytical algorithms to enable precise quantification of liver fibrosis.”
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 3
Wei, J., Wang, L., Zebin, M., & Zhang, P. (2026) · Biology · doi:10.3390/biology15030233 · Cited by 1
Chang, Y. W., Cho, Y. K., Kim, Y. S., Kim, S. E., Cheon, G. J., Kim, J. H., Yang, H. J., Kim, W., Ahn, S. B., Yoon, E. L., et al. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e89 · Cited by 1
Metabolic Liver Disease Beyond the Liver
Gastaldelli, A., Tacke, F., & Holleboom, A. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.003 · Cited by 1
Metabolische Lebererkrankungen bei Adipositas
Horn, P., & Tacke, F. (2026) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2722-1114 · Cited by 1
Therapeutic Opportunities Targeting the ACE2/Ang-(1–7)/MasR Pathway in Cardiometabolic Disease
Jayawardena, T. U., Nagahawatta, D. P., Grant, M. B., Chappell, M. C., & Oudit, G. Y. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01364-9 · Cited by 1
Current management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
Dong, S., Xu, Y., Gan, R., Zhang, A., He, J., & Tang, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70049 · Cited by 1
The expanding landscape of the glucagon signaling network: mechanisms and outcomes
Foollee, A., Wu, Y., Rusu, P. M., & Rose, A. J. (2026) · Endocrinology · doi:10.1210/endocr/bqag041 · Cited by 1
Merrild, C., Johansen, V. B. I., Clemmensen, C., & Ranea‐Robles, P. (2026) · The Journal of Physiology · doi:10.1113/jp289817 · Cited by 1
Tsutsumi, T., Tang, N. S. Y., Ng, C. H., Suzuki, H., Syn, N. L., Sasikumar, N. A., Ho, G. J. K., Chua, D., Tioh, J. K., Pramotedham, T., et al. (2026) · Med · doi:10.1016/j.medj.2026.101077 · Cited by 3
Self-citationMASH and liver fibrosis: Clinical trials to watch
Zhang, X., & Wong, V. W. (2026) · Med · doi:10.1016/j.medj.2026.101069 · Cited by 1
Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management
Lai, K. N., & Wong, V. W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-167 · Cited by 2
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Lifespan approaches for the prevention and management of steatotic liver disease
Zelber‐Sagi, S., Ivancovsky-Wajcman, D., Kugelmas, C., Weinstein, A. A., Wong, V. W., Castéra, L., Moore, J. B., Mouzaki, M., Hallsworth, K., Paik, J. M., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01198-5 · Cited by 2
“Newer incretin therapies target GLP1, glucose-dependent insulinotropic polypeptide (GIP), and/or glucagon receptors simultaneously, and might prove more effective in reversing MASH and fibrosis 233,234 .”
Lee, R. S. M., Seah, J., Baqar, S., Srivastava, P., Levelt, E., Leet, A. S., MacIsaac, A. I., Ekinci, E. I., & MacIsaac, R. J. (2026) · Medicina · doi:10.3390/medicina62050870 · Cited by 2
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 2
吴学碧, Ma, Y., Yin, X., Liu, J., & Zhang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863710 · Cited by 1
Yokote, K., Yamauchi, T., Fukushima, Y., Takatsuka, Y., Kato, M., Yan, S., Inoue, T., Borowska, L., Brueckmann, M., Ogawa, W., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70862 · Cited by 1
Incretin-based therapies: a new era in metabolic liver disease management
Elangovan, S., Cheah, C. C. M., & Goh, G. B. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.15 · Cited by 1
MASLD as Complication of Diabetes
Stefan, N. (2026) · Diabetes · doi:10.2337/dbi26-0001 · Cited by 4
Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation
Dunn, W., & Alkhouri, N. (2026) · Med · doi:10.1016/j.medj.2026.101172 · Cited by 2
Self-citationVozza, A., Biagi, F., Chiara, R., Vizzutti, F., & Marra, F. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04456-1 · Cited by 1
“Survodutide, a dual GLP-1/glucagon receptor agonist, significantly improved MASH without worsening of fibrosis in a phase 2 trial and also reduced liver fat content [65].”
Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies
Tang, Q., Li, J., Song, H., Zhang, A., Zeng, H., Xu, Y., Mo, L., & He, J. (2026) · Advanced Science · doi:10.1002/advs.76747 · Cited by 1
Kushner, P. R., & Michos, E. D. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049727 · Cited by 2
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Li, S., Toutoungy, M., Patel, J., Bhavsar‐Burke, I., & VanWagner, L. B. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01380-9 · Cited by 2
“In a phase 2b trial, survodutide achieved MASH resolution in 47–62% of patients versus 14% with placebo, with fibro - sis improvement in 32–36% versus 18% over 48 weeks [103].”
Lower glucagon response and attenuated hepatic glucagon signaling in MASLD
Kim, S. R., Hwang, Y., Lee, M., Choi, A., Lee, B., Kang, E. S., Cha, B., Kim, K. J., & Lee, Y. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101787 · Cited by 1
Zhu, L., & Wu, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1899587 · Cited by 1
Ayoub, M., Tsutsumi, T., & Rinella, M. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70921 · Cited by 2
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“Survodutide has shown dose-dependent weight reduction in phase 2 obesity trials and has also demonstrated histological benefits in metabolic dysfunction-associated steatohepatitis, suggesting potential relevance for obesity-related hepatic and cardiometabolic complications [43,44].”
Oh, J. H. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0062 · Cited by 1
“2024 년 resmetirom [ 7 ]과 2025 년 semaglutide 의 FDA 승인 대한의사협회지 [ 8 ], 그리고 tirzepatide [ 9 ]와 survodutide [ 10 ] 등”
You, Z., Yang, L., Long, Y., You, D., & Zhao, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815576 · Cited by 1
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
“10,68 Consistent with these findings, evidence from real-world studies and prescription/ renewal analyses suggests relatively high discontinuation rates with GLP-1-based therapies over time, reaching approximately 30%–50% within the first year, likely driven by gastrointestinal tolerability, which…”
Li, T. (2025) · International Conference on Biomedical and Intelligent Systems (IC-BIS) · doi:10.1145/3745034.3745046 · Cited by 1
“This includes information about drug effectiveness, safety, patient compliance, and the socio-economic advantages of various treatment choices, as it covers long-term use of drugs in clinical settings [3].”
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Gómez-Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502352 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
“GLP-1 RAs, dual GLP-1/GIP RAs, and pioglitazone are the preferred of fibrosis up to 62% (4.8 mg weekly dose) compared to 14% with placebo, in a phase 2 clinical trial that included 293 patients [35].”
InfluentialHoegeman, K. M., Wotring, J. W., Fursmidt, R. M., Gaetz, J., Khalil, E. M., Selinger, D. W., Kovalenko, I., Schultz, T. L., McCarty, S. M., O’Meara, M. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.693988 · Cited by 2
“70 73 Beyond glycemic control, preclinical and clinical evidence suggests that enhancing GLP-1 signaling may also exert beneficial effects on the liver in the context of MASLD.”
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502639 · Cited by 1
A trio of trials on hormone receptor agonists for MASLD
Starling, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01015-6
Mathematical Modelling of MASLD ‐ Towards Digital Twins in Liver Disease
Simonsson, C. (2024) · Linköping studies in science and technology. Dissertations · doi:10.3384/9789180757348
Wagner, R. J. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2384-6105
JPEN Journal Club 88. Determining the hypothesis of a study
Koretz, R. L. (2024) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2696
Cirrhose métabolique : une entité en plein essor
Ratziu, V. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.11.012
Self-citationBaktikulova, K., Kurmangaliyeva, S. S., Kurmangaliyev, K. B., Makashova, M., Tissin, K., & Madenbayeva, A. M. (2024) · Research Square · doi:10.21203/rs.3.rs-5648355/v1
Urbańska, K., Popiela, D., Stojak, Ł., Kwiatkowski, F., Grego, K., Grego, M., Baczewski, M., & Czyż, W. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57002
MASH: Survodutid bessert Steatohepatitis und Fibrose
Krome, S. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2392-2365
Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
Hussein, M. T. E., & Favell, D. (2025) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105273
The significance of metabolism-associated steatotic liver disease and its treatment
Vašura, A., Machytka, E., Bužga, M., Macháčková, J., & Král, J. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.005
Inkretin-(Co-)Agonisten: Wo geht die Reise hin?
Sonnet, M. (2025) · Info Diabetologie · doi:10.1007/s15034-024-5066-z
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
Pradeepthi, B., Ahmed, N., supriya, J., Manogna, A., Padamati, R. K., Murty, R. S., & Kiranmai, K. (2025) · Research Square · doi:10.21203/rs.3.rs-6604350/v1
Pagès, L., Martí‐Carretero, A., Rojo, D., Sabiote, C., Faninam, F., Parks, S. C., Martínez-Gómez, M., Cusidó, M. S., Akhlaghi, N., Muñoz, S., et al. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00692-9 · Cited by 1
Diabetes und metabolische-Dysfunktion-assoziierte steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01346-6
Metadata
- Authors
- Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., Hosseini-Tabatabaei, A., Schattenberg, J. M., Noureddin, M., Alkhouri, N., & Younes, R.
- Affiliations
- Inserm (FR)
- From the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); Liverpat and University of Paris (P.B.), and Sorbonne Université, Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris, INSERM Unité Mixte de Recherche Scientifique 1138, Centre de Recherche des Cordeliers (V.R.) — all in Paris; Boehringer Ingelheim, Ingelheim am Rhein (M.F., S.A.H and R.Y.), Saarland University Medical Center, Homburg (J.M.S.), and University of the Saarland, Saarbrücken (J.M.S.) — all in Germany; Covenant Metabolic Specialists, Sarasota, FL (G.W.N.); Houston Methodist Hospital and Houston Research Institute, Houston (M.N.), and the Texas Liver Institute, University of Texas Health San Antonio, San Antonio (E.L. and N.A.) — all in Texas; the University of Turin, Turin, Italy (E.B.); the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, and Newcastle National Institut...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 311-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399439504
- Cited by
- 528
- References
- 28
- Citations by year
- 2026: 212 · 2025: 237 · 2024: 79
- FWCI
- 159.28
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- survodutide, nonalcoholic steatohepatitis, liver fibrosis, glucagon receptor agonist, GLP-1 receptor agonists, liver fat, histologic improvement, dose-response relationship, adverse events, non-alcoholic fatty liver disease, drug safety and efficacy, dose escalation, maintenance phase
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Receptors, Glucagon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.